Journal
CELL TRANSPLANTATION
Volume 20, Issue 9, Pages 1453-1463Publisher
SAGE PUBLICATIONS INC
DOI: 10.3727/096368910X552853
Keywords
Cord blood; CD34(+) cells; Ex vivo expansion; Progenitors; Stem cells; NOD/SCID mice
Funding
- Aquitaine-Limousin Branch of French Blood Institute (Bordeaux)
Ask authors/readers for more resources
We developed a clinical-scale cord blood (CB) cell ex vivo procedure to enable an extensive expansion of committed progenitors-colony-forming cells (CFCs) without impairing very primitive hematopoietic stem cells (HSCs). CD34(++) cells, selected from previously cryopreserved and thawed CB units, were cultured in two steps (diluted 1:4 after 6 days) in the presence of stem cell factor (SCF), fms-related tyrosine kinase 3 ligand (Flt-3L), megakaryocyte growth and development factor (MGDF) (100 ng/ml each), granulocyte-colony stimulating factor (G-CSF) (10 ng/ml) in HP01 serum-free medium. HSC activity was evaluated in a serial transplantation assay, by detection of human cells (CD45, CD33, CD19 and CFC of human origin) in bone marrow (BM) of primary and secondary recipient NOD/SCID mice 6-8 weeks after transplantation. A wide amplification of total cells (similar to 350-fold), CD34(+) cells (similar to 100-fold), and CFC (similar to 130-fold) without impairing the HSC activity was obtained. The activity of a particular HSC subpopulation (SRCCPC) was even enhanced. Thus, an extensive ex vivo expansion of CFCs is feasible without impairing the activity of HSCs. This result was enabled by associating antioxidant power of medium with an appropriate cytokine cocktail (i.e., mimicking physiologic effects of a weak oxygenation in hematopoietic environment).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available